首页 | 本学科首页   官方微博 | 高级检索  
     

拉帕替尼合成工艺研究
引用本文:张庆文, 周后元, 尤启冬. 拉帕替尼合成工艺研究[J]. 中国药科大学学报, 2010, 41(4): 317-320.
作者姓名:张庆文  周后元  尤启冬
作者单位:1.上海医药工业研究院化学制药部;2.中国药科大学药学院
基金项目:国家“重大新药创制”科技重大专项资助项目(No.2009ZX09301-007);上海市基础研究重点项目(No.09JC1413200)
摘    要:报道了拉帕替尼二对甲苯磺酸盐一水合物( 1 )的合成工艺研究。以6-碘喹唑啉-4-酮( 3 )为起始原料,依次经氯化反应(收率88%)、与5-甲酰基呋喃-2-硼酸的Suzuki偶联反应(收率96%)、与2-(甲砜基)乙胺的还原胺化(收率94%)、与一水合对甲苯磺酸成盐(收率87%)和四氢呋喃-水(8∶2)结晶(收率70%)等5步操作制备目标产物 1 ,总收率48%。各中间体和目标产物经1H NMR、13C NMR、ESI-MS表征。在工艺优化中革除了柱色谱及对环境不友好的过量氯化剂、含卤溶剂,采用易于回收的非均相催化剂钯炭替代昂贵和难以处理的均相催化剂。所研制的合成工艺路线各步收率均较高,而且操作简便,无需特殊试剂和条件,预期适合工业化生产的要求。

关 键 词:拉帕替尼  酪氨酸激酶抑制剂  合成工艺  分子靶向治疗  抗肿瘤药

Practical synthesis of lapatinib
Practical synthesis of lapatinib[J]. Journal of China Pharmaceutical University, 2010, 41(4): 317-320.
Abstract:This paper deals with the development of a practical process for lapatinib tosylate monohydrate(〖STHZ〗1〖STBZ〗),a molecule-targeted antitumor agent.The target product 1 was synthesized from commercially available 6-iodoquinazolin-4-one( 3 in a five-step process with an overall yield of 48% via chlorination(88% yield),palladium carbon catalyzed Suzuki coupling with 5-formyl-2-furylboronic acid(96% yield),reductive amination with 2-(methylsulfone)ethylamine(94% yield),salt formation with p-toluenesulfonic acid monohydrate(87% yield),and final crystallization from THF-water (8∶2) (70% yield).The intermediates and the target product were characterized by melting points,1H NMR,13C NMR,and ESI-MS.During our optimized process,chromatography,large excess of chlorinating agent and halogenated solvent that are unfriendly to the environment were all removed;expensive and difficult-to-handle homogeneous catalyst was successfully substituted with heterogeneous catalyst palladium carbon which could be recovered easily.In conclusion,this streamlined synthetic process of lapatinib tosylate monohydrate( 1 ) highlights excellent yield in almost every procedure,ease of operation,robustness,as well as green chemistry,and thus should be amenable to large-scale production.
Keywords:lapatinib  tyrosine kinase inhibitor  synthetic process  molecule-targeted therapy  antitumor agents
点击此处可从《中国药科大学学报》浏览原始摘要信息
点击此处可从《中国药科大学学报》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号